{"entity":{"id":"nct07579234","kind":"trial","name":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 3 trial testing F182112 in multiple myeloma, now recruiting.","summary":"A Multicenter, Randomised, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07579234, led by Shandong New Time Pharmaceutical, and recruiting on the registry. Official title: Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma. Planned enrolment is 261 participants (estimated). The study started in 2026-01-25 and primary completion is expected in 2029-01-25. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07579234","url":"https://clinicaltrials.gov/study/NCT07579234"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["f182112"],"companies":["shandong-new-time-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07579234","phase":"3","setting":"Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Shandong New Time Pharmaceutical","started":"2026-01-25","startedType":"actual","enrolled":261,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07579234/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"f182112","kind":"drug","name":"F182112","route":"/drugs/f182112/"}],"company":[{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","route":"/companies/shandong-new-time-pharmaceutical/"}]}}